Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE) filed a Form 8-K on November 7, 2024, to announce financial results and operational updates for the three months ended September 30, 2024. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2), which are referenced but not detailed in the body of this 8-K report.
Material Changes
No specific material changes versus the prior comparable period are quantified in the filing text. The report serves as a notification that the company has issued a press release containing these results.
Guidance, Outlook, and Risks
- Operational Update: The company provided an update on its operations for the period ended September 30, 2024, via the attached press release.
- Corporate Presentation: The company updated its corporate presentation slide deck, filed as Exhibit 99.2.
- Legal Disclaimer: The information in Item 2.02 and the attached exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2024 financial figures including cash position and burn rate.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines and strategic outlook.
- Verify the company's cash runway and any recent financing activities not detailed in this summary.
- Confirm the status of emerging growth company election and its impact on financial reporting standards.